JP2007514763A - Ｃ型肝炎ウイルス（ｈｃｖ）の感染を処置するための組成物および方法 - Google Patents

Ｃ型肝炎ウイルス（ｈｃｖ）の感染を処置するための組成物および方法 Download PDF

Info

Publication number
JP2007514763A
JP2007514763A JP2006545542A JP2006545542A JP2007514763A JP 2007514763 A JP2007514763 A JP 2007514763A JP 2006545542 A JP2006545542 A JP 2006545542A JP 2006545542 A JP2006545542 A JP 2006545542A JP 2007514763 A JP2007514763 A JP 2007514763A
Authority
JP
Japan
Prior art keywords
carboxylesterase
compound
inhibitor
composition
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006545542A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007514763A5 (enExample
Inventor
エリズビータ ジェイ． ホルズィンスカ，
レイ ロー，
トーマス ダブリュー． サン，
スティーブン エックス． ワン，
Original Assignee
ライジェル ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ライジェル ファーマシューティカルズ， インコーポレイテッド filed Critical ライジェル ファーマシューティカルズ， インコーポレイテッド
Publication of JP2007514763A publication Critical patent/JP2007514763A/ja
Publication of JP2007514763A5 publication Critical patent/JP2007514763A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2006545542A 2003-12-19 2004-12-18 Ｃ型肝炎ウイルス（ｈｃｖ）の感染を処置するための組成物および方法 Pending JP2007514763A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53154303P 2003-12-19 2003-12-19
PCT/US2004/042717 WO2005063225A1 (en) 2003-12-19 2004-12-18 Compositions and methods for treating hepatitis c virus (hcv) infection

Publications (2)

Publication Number Publication Date
JP2007514763A true JP2007514763A (ja) 2007-06-07
JP2007514763A5 JP2007514763A5 (enExample) 2008-02-14

Family

ID=34738664

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006545542A Pending JP2007514763A (ja) 2003-12-19 2004-12-18 Ｃ型肝炎ウイルス（ｈｃｖ）の感染を処置するための組成物および方法

Country Status (7)

Country Link
US (1) US20050249805A1 (enExample)
EP (1) EP1699446B1 (enExample)
JP (1) JP2007514763A (enExample)
AT (1) ATE396718T1 (enExample)
DE (1) DE602004014189D1 (enExample)
ES (1) ES2308302T3 (enExample)
WO (1) WO2005063225A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7971730B2 (en) 2005-08-10 2011-07-05 The Regents Of The University Of California Collection tubes apparatus, systems and methods
JP2010528666A (ja) * 2007-06-08 2010-08-26 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント カルボキシエステラーゼ−１多型およびその使用方法
US20090017108A1 (en) * 2007-07-11 2009-01-15 Alexander Yuzhakov Liposome compositions for treatment of hepatitis C
US8182826B2 (en) * 2007-09-11 2012-05-22 Whitmire A Jeffrey Refreshment towel and applied solution
US10966431B2 (en) * 2007-09-11 2021-04-06 Freedom Towel Holdings, LLC. Refreshment towel and applied solution
US9669405B2 (en) 2012-10-22 2017-06-06 The Regents Of The University Of California Sterilizable photopolymer serum separator
US10154947B2 (en) 2016-01-06 2018-12-18 The Procter & Gamble Company Antiperspirant composition
US9730867B2 (en) 2016-01-06 2017-08-15 The Procter & Gamble Company Methods of forming a slurry with microcapsules formed from phosphate esters
US9732303B2 (en) 2016-01-06 2017-08-15 The Procter & Gamble Company Microcapsules formed from phosphate esters and compositions containing same
CN110220757B (zh) * 2019-06-05 2021-08-24 浙江龙传生物医药科技有限公司 用于药物代谢检测的血液保存剂

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002046186A1 (en) * 2000-12-08 2002-06-13 Takeda Chemical Industries, Ltd. Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4971618A (en) * 1971-04-16 1990-11-20 Ici Americas Inc. Herbicide compositions
PL374536A1 (en) * 2002-08-23 2005-10-31 Rigel Pharmaceuticals, Inc. Pyridyl substituted heterocycles useful for treating or preventing hcv infection

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002046186A1 (en) * 2000-12-08 2002-06-13 Takeda Chemical Industries, Ltd. Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof

Also Published As

Publication number Publication date
ES2308302T3 (es) 2008-12-01
US20050249805A1 (en) 2005-11-10
EP1699446B1 (en) 2008-05-28
WO2005063225A8 (en) 2005-08-25
DE602004014189D1 (de) 2008-07-10
ATE396718T1 (de) 2008-06-15
WO2005063225A1 (en) 2005-07-14
EP1699446A1 (en) 2006-09-13

Similar Documents

Publication Publication Date Title
Rais et al. Discovery of 6-diazo-5-oxo-l-norleucine (DON) prodrugs with enhanced CSF delivery in monkeys: a potential treatment for glioblastoma
Tenora et al. Tumor-targeted delivery of 6-diazo-5-oxo-l-norleucine (DON) using substituted acetylated lysine prodrugs
US20100291216A1 (en) Pharmaceutical compositions
CA2662542A1 (en) Pharmaceutical composition comprising a plurality of mini-tablets comprising a factor xa inhibitor
CN1261791A (zh) 诊断或治疗用途的靶向脂质体构建物
Mustata et al. Approaches to oral drug delivery for challenging molecules
CA2581764A1 (en) Minicapsule formulations
JP2007514763A (ja) Ｃ型肝炎ウイルス（ｈｃｖ）の感染を処置するための組成物および方法
Breschi et al. NO-sartans: a new class of pharmacodynamic hybrids as cardiovascular drugs
CN101528747A (zh) 3-(二氢-1H-吡唑并[4,3-d]嘧啶-5-基)-4-丙氧基苯磺酰胺衍生物和使用方法
EP1585500B1 (en) Coated particles for sustained-release pharmaceutical administration
CN105102438A (zh) 抗炎症和抗肿瘤的2-氧代噻唑类和2-氧代噻吩类化合物
US20210179535A1 (en) Alpha-truxillic acid derivatives and pharmaceutical compositions thereof
US20200148617A1 (en) Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor
CA3217972A1 (en) Pharmaceutical compositions for treating neurological conditions
TW200529821A (en) Simvastatin formulations and methods of making same
WO2023283427A2 (en) Enteric and delayed release formulations of locally bioavailable drugs (lbd) targeting the colon
US20200253877A1 (en) Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor
CH710991A2 (fr) Compositions comprenant des combinaisons d'analogues de la 4,5-diacétylrhéine et des inhibiteurs de carboxylestérases mammaliennes.
Challener Excipients for Solubility Enhancement of Parenteral Formulations
JP7486202B2 (ja) 化合物の抗ｐｃｓｋ９（抗プロタンパク質変換酵素スブチリシン ケキシン９型）ナノ製剤および心血管疾患の治療および／または予防におけるその使用方法
Ben Taleb et al. Antitumor efficacy of ceranib-2 with nano-formulation of PEG and rosin esters
US12503422B2 (en) Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor
Taha Bioavailability assessment of hydroxymethylglutaryl coenzyme A reductase inhibitor utilizing pulsatile drug delivery system: a pilot study
US20230218616A1 (en) Combinations for Treatment of NAFLD/NASH and Related Diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110913

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120328